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Abstract
Introduction—We describe Alzheimer’s Disease Neuroimaging Initiative (ADNI) Biomarker 
Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1–42), t-tau, and 
p-tau181 analytical performance, definition of Alzheimer’s disease (AD) profile for plaque, and 
tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; 
progress in standardization; and new studies using ADNI biofluids.
Methods—Review publications authored or coauthored by ADNI Biomarker core faculty and 
selected non-ADNI studies to deepen the understanding and interpretation of CSF Aβ1–42, t-tau, 
and p-tau181 data.
Results—CSFAD biomarker measurements with the qualified AlzBio3 immunoassay detects 
neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies 
in non-ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across 
ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals 
because of genetic/environmental factors that increase/decrease resilience to AD pathologies.
Discussion—Further studies will refine this model and enable the use of biomarkers studied in 
ADNI clinically and in disease-modifying therapeutic trials.
Keywords
Alzheimer’s disease; Mild cognitive impairment; Cerebrospinal fluid; Plasma; Biomarkers; 
Immunoassay; ADNI; Disease-modifying therapy; Aβ1–42; Tau
1. Introduction
Alzheimer’s disease (AD), the most common form of dementia [1,2]. It is a complex 
progressive neurodegenerative disease that leads to the loss of memory and cognitive 
function. The disease is pathologically characterized by amyloid-β (Aβ) plaques and 
neurofibrillary tangles (NFTs) that are composed largely of fibrillar forms of Aβ and 
hyperphosphorylated tau (p-tau), respectively. During the past two decades cumulative 
molecular and clinical studies have provided evidence for our understanding of the 
molecular characteristics and progressive pathologic features of AD. These pathologic 
changes are reflected in cerebrospinal fluid (CSF), respectively, by lowered levels of Aβ1–42 
followed by increased total tau (t-tau) or p-tau181. In the Biomarker Core of the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI-1) located at the Perelman School of Medicine of 
the University of Pennsylvania (Penn), we defined cut points for the use of these biomarkers 
and their ratios using an ADNI-independent autopsy-based Penn AD cohort and age-
matched living normal control (NC) subjects. Cognitive decline in AD patients closely 
correlates to neurofibrillary tangles (NFTs), synapse loss, and neurodegeneration [3–5]. 
However, there is a growing awareness for the occurrence of one or more copathologies in 
sporadic AD including Lewy bodies (LBs), vascular disease, transactive response DNA 
binding protein 43 kDa (TDP-43) inclusions, and hippocampal sclerosis which most likely 
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contributes to the variable timeline for the progression of AD [6] as reflected in the imaging, 
CSF biomarkers, and clinical features of patients with dementia of the AD type (DAT) (Fig. 
1).
AD can be divided into different phases: (1) a preclinical phase in which subjects are 
cognitively normal but have mild AD pathology, (2) a prodromal phase known as mild 
cognitive impairment (MCI), and (3) a phase when patients show dementia with 
impairments in multiple domains and loss of function in activities of daily living [4,7–9]. On 
the basis of the prevailing scientific evidence, CSF Aβ1–42 and the tau proteins have been 
incorporated into the revised research diagnostic criteria for AD together with β-amyloid 
positron emission tomography (PET) imaging [10–13], and tau amyloid PET imaging is now 
also available [14,15]. It is being added to the ADNI portfolio of imaging technologies. 
ADNI-1 studies reported evidence of AD pathology in one-third of the cognitively intact 
elderly NC subjects solely based on CSF Aβ1–42 [16,17]. It is time to consider developing 
strategies to identify AD at the presymptomatic and prodromal phases to optimize the 
potential efficacy of disease-modifying therapies, and to enable drug development aimed at 
AD prevention. A key goal of ADNI continues to be the improvement of the standardization 
of biomarker measurements to enable their use in clinical AD trials, across multiple testing 
laboratories, and in routine clinical practice. Thus, the standardization of both preanalytical 
(at the level of biofluid sample collection, handling, aliquot preparation, and storage) and 
analytical sources of variability continues to be a priority of the Penn Biomarker Core and 
we continue to collaborate with biomarker scientists on these issues. We participated in 
recent consensus group and we are part of the Alzheimer’s Biomarker Standardization 
Initiative, providing a set of recommendations for 10 preanalytical factors [18]. We have 
continued the work of analytical method standardization in the Penn Biomarker Core of 
ADNI and also have collaborated with colleagues in the Global Biomarker Standardization 
Consortium (GBSC) in support of Aβ1–42 calibrator standardization, based on mass 
spectrometry, across various immunoassay platforms [19]. We expect that an outcome of all 
these efforts will be the availability of the most highly standardized methods for CSF Aβ1–42 
and tau proteins. In this review, we summarize progress by the Penn Biomarker Core of 
ADNI using the developed pathological CSF biomarker profile that sensitively detects Aβ 
amyloid plaque burden (below the threshold for the CSF Aβ1–42 concentration) and NFTs, 
synapse loss, and neurodegeneration (above-threshold for CSF tau protein concentrations) 
[16]. We continue the collaborative work to develop biomarker tests for α-synuclein (α-syn) 
to indicate the presence of concomitant LBs and forTDP-43 as an indicator of inclusions of 
this biomarker in early AD, early and late MCI, and NC subjects. The Penn Biomarker Core 
has collaborated with other ADNI Cores in multimodal data analyses across ADNI to 
temporally order changes in clinical measures, imaging data, and chemical biomarkers that 
refine and expand our understanding and interpretation of the pathophysiology involved in 
the disease progression from NC to MCI and from MCI to AD. The hypothetical model of 
the temporal evolution of changes in the AD biomarkers will be further developed within the 
Biomarker Core studies in the ADNI-2 grant (Fig. 1) and informs our plans for the ADNI-3 
competing renewal application.
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2. Biofluid repository update
2.1. Overview
From 2010 through 2015, the ADNI-1 and II biofluid repository at Penn continuously 
receives biofluids (CSF, plasma, and serum) shipped from all ADNI sites followed by 
aliquoting and monitoring after storage in −80°C freezers. This effort requires 24/7 attention 
by the Penn Biomarker Core team. Since its inception in 2004, no lost samples or other 
untoward misadventures were recorded. The biofluid samples are collected and shipped in 
accordance with ADNI biomarker standard operating procedures (SOPs) established in 
ADNI-1 after consultation with members of the Private Partners Scientific Board (PPSB) 
and other ADNI advisory biomarker scientists. We continue to work closely with the ADNI 
Clinical Core on recording essential details for each collected sample from the jointly 
developed biofluid tracking form. These SOPs are essential to ensure the integrity of 
samples, accurate identification of the samples received and aliquots prepared from them, 
and sample stability. Continuous vigilance of the characteristics of each received sample by 
Biomarker Core staff and regular communication with Clinical Core staff and individual 
sites regarding any issues that may arise involving mislabeled samples or other issues has 
enabled the correction of the issues related to this function of the Biomarker Core, and the 
regular communication between this Core and the ADNI sites facilitates the collection of 
accurate data for every collected sample.
2.2. Current status of the ADNI biofluid bank
2.2.1. ADNI-1, 2, and Grand Opportunity—From April 21, 2010 and from March 7, 
2011, the dates that the first ADNI-Grand Opportunity (GO) and first ADNI-2 biofluid 
samples were received, respectively, through January 26, 2015, a total of 9461 biofluids 
were received, processed, and 164,120 aliquots prepared (1279 CSF, 8182 plasma, and 
serum samples; 39,561 CSF aliquots, 124,559 plasma and serum aliquots), bar code labeled, 
and stored in dedicated ADNI freezers at −80°C (Fig. 2). The totals for ADNI-1, ADNI-2, 
and ADNI-GO are summarized in Fig. 2. Temperature monitoring of each freezer is done 
everyday, 365 days a year, with a telephone alarm system, and one Penn Biomarker Core 
staff person is always “oncall” to respond to an alarm. For each primary biofluid sample 
collected, the following information is maintained in the ADNI Biomarker Core database at 
Penn: biofluid type (CSF, plasma, serum, urine [only ADNI-1]), coded subject and visit ID, 
six digit license plate number, visit date and time, date and time of receipt, condition of 
samples as received, biofluid sample volume and number of aliquots, and the details of 
sample preparation such as time from collection to time of transfer, and to time of freezing 
are recorded for each sample from each study site. The database is backed up daily on each 
of two external “brick” hard drives. The latter are stored outside the Biomarker Core 
laboratory in a secure location in a different building to ensure data security in the event of a 
catastrophic failure of the server in which the database resides.
2.2.2. Rationale for sample preparation preanalytical steps—The preanalytical 
steps involved in sample preparation and the analytical method itself are two well-known 
sources of variability in CSF biomarker measurements. An important basis for the 
preparation procedure for samples at each ADNI site was the principle of keeping the 
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number of steps involved to the minimum and keeping the time at room temperature before 
freezing samples on dry ice to the minimum practically possible. For example, CSF samples 
are collected in labeled polypropylene collection tubes followed by transfer to labeled 
polypropylene transfer tubes (n = 2), with no centrifugation step, then are placed on dry ice 
immediately, and shipped on dry ice to the Penn ADNI Biomarker Core laboratory where 
they subsequently are thawed at room temperature. Within 30 minutes of thawing the CSFs 
are aliquoted into 0.5-mL polypropylene tubes and placed in storage boxes in designated 
locations in −80°C freezers. This streamlined process does include one additional thaw–
freeze step compared with protocols that prepare and label individual aliquots at local sites 
but reduces risk for variable sample preparation and contributes to consistency of sample 
handling in our experience. The data on sample preparation times for ADNI biofluids are 
summarized in Fig. 2 showing average times of 52.4 and 75.5 minutes from sample 
collection to freezing the samples for CSF and plasma, respectively. The fastidiousness with 
which staff at the ADNI sites prepare and ship biofluid samples is noteworthy. The use of 
centrifugation of CSF before freezing has been a debated topic but investigators have shown 
for Aβ1–42 and tau proteins no difference in results comparing centrifuged versus not 
centrifuged samples [18]. A just published systematic study of preanalytical factors 
confirmed the lack of effect of not-centrifuging versus centrifugation of CSF samples and 
also the stability of Aβ1–42 and tau protein concentrations out to three freeze–thaw cycles 
but with decreases after four cycles for Aβ1–42 and t-tau but not p-tau181 [127]. The use of a 
second thaw–freeze cycle in the ADNI study for CSF samples is within the observed 
stability in this and other studies (data on file in the ADNI Biomarker Core laboratory).
2.2.3. Shipments of biofluid aliquots to investigators for studies approved by 
the ADNI National Institute on Aging(NIA) Resource Allocation Review 
Committee—An integral part of the responsibilities of the Penn Biomarker Core is to 
respond to requests for biofluids that are approved by the Resource Allocation Review 
Committee (RARC). The 18 RARC-approved requests for ADNI biofluids are summarized 
in the latest edition of the annual Biofluids reports that are available on the Laboratory of 
Neuroimaing (LONI) ADNI website (https://ida.loni.usc.edu/pages/access/studyData.jsp?
categoryId=11&subCategoryId=58).
Results from the most recent downloaded and published studies are discussed in later 
sections of this review.
3. Qualification of the analytical performance of CSF biomarker 
immunoassays
With the development of Aβ1–42, total tau (t-tau), and tau phosphorylated at threonine 181 
(p-tau181)-specific monoclonal antibodies, efforts to develop singleplex and multiplex 
platforms to measure the AD biomarkers in human CSF have emerged. Based on reported 
studies, the precision performance of the enzyme-linked immunosorbent assay (ELISA) and 
multiplex Luminex-xMAP platforms, two of the most widely used platforms for the 
measurement of CSF biomarkers, supports their intended use to detect AD Aβ plaque and 
NFT pathology by measuring CSF Aβ1–42 and tau [20]. ADNI adopted the Luminex xMAP 
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platform and the multiplex INNO-BIA Alz-Bio3 immunoassay to measure the CSF AD 
biomarkers based on reported within-center precision performance and equivalent clinical 
utility to that of the INNOTEST ELISA immunoassay [21]. Precision performance was most 
recently documented for 133 runs, using four different kit lots, and completed over the time 
frame from August 2013 through January 2015. The study included a formally outlined, 
prospective quality control strategy [20]. Using an AD-like abnormal CSF and a normal CSF 
pool, the percent coefficient of variation (%CV) values obtained were 9.2% and 10.2%, 
7.4% and 10.1%, 11.2% and 12.2%, for respectively, Aβ1–42, t-tau, and ptau181 using the 
Luminex-xMAP platform in the Penn ADNI Biomarker Core laboratory [22], which 
confirmed previously published within-center data [23].
Of note, the concentrations of each biomarker measured by xMAP in the same CSF samples 
differ from those measured by ELISA, although the concentrations are highly correlated 
[24–26]. Several studies including a study led by the ADNI Biomarker Core assessed the 
interlaboratory variability of the CSF AD biomarkers described previously. Briefly, these 
studies showed that following a well-vetted protocol the substantial intercenter variability of 
both immunoassay platforms [23,27,28] can be improved on. The studies suggested that 
several factors can account for interlaboratory variability for CSF AD biomarker 
measurements. Besides preanalytical factors, for instance, any analytical step not included in 
the manufacturer’s formal protocol (e.g., repeated pipetting of reagents or samples, transfer 
of samples to an intermediary 96-well plate, differences in data processing, selection of 
calibration curves, criteria used for acceptance of individual runs based on internal quality 
control samples) that might be used by analysts can be a significant source of unexpected 
variability.
Our recent application of a unified detailed test procedure for the Luminex INNO_BIA 
AlzBio3 platform across three independent laboratories showed acceptable interlaboratory 
variation. In this pilot study, we observed a strong correlation of concentrations for each 
analyte between the participating centers (R2 > 0.95; linear regression: center versus overall 
center mean) and average total interlaboratory variability for 10 pools of CSF (variability 
components “run” and “lab”) over eight runs were 16.5% for t-tau, 10.9% for Aβ1–42, and 
9.2% for p-tau181. Therefore, we are convinced that the implementation of a unified SOP, 
careful documentation of critical parameters of the test procedure, and the rigorous 
adherence to detailed test instructions can result in improved CSF analyte concentration 
reproducibility across laboratories [29]. In addition, the experience of trained personnel who 
are very familiar with this complex procedure is essential to decrease variability. Further 
improvements in immunoassay performance within and between centers can be anticipated 
as manufacturers develop fully automated platforms that will reduce substantially the 
number of manual steps and minimize matrix interferences. A proof-of-principle study 
reported by Figurski et al showed that combining the standard bead-based xMAP plasma 
Aβ1–42 immunoassay with a robotic pipetting technique achieved a 50% improvement in 
precision performance compared with other published studies [30].
Kang et al. Page 6
Alzheimers Dement. Author manuscript; available in PMC 2016 November 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Progress in clinical utility of CSF AD biomarkers
4.1. CSF Aβ1–42, t-tau, and p-tau181 measurements
CSF Aβ1–42, t-tau, and p-tau181 have been extensively studied for the early detection of AD 
before and after the start of ADNI in 2004 [31–35]. For the ADNI Biomarker Core, the 
publication by Shaw et al. [16] was a major milestone (Table 1). It reported cut points using 
Receiver Operating Characteristic (ROC) analysis for the discrimination of AD patients 
from NC subjects based on an ADNI-independent autopsy-confirmed cohort. The defined 
cut points were successfully applied to the ADNI-1 cohort and these values have been used 
in many other clinical studies [36] and clinical trials. DeMeyer and collaborators 
independently confirmed the clinical utility of these cut points using a mixture-modeling 
approach in the ADNI-1 study subjects and in an ADNI-independent Belgian autopsy-based 
study cohort [17]. Toledo and coworkers provided additional validation data using more than 
1000 ADNI subjects (ADNI 1, GO, 2), including follow-up samples. Mixture modeling 
approaches applied to CSF in combination with PETAβ amyloid imaging data led to 
converging cut point values similar to the previously established levels [37] (Table 1).
Two independent analyses of the ADNI-1 data set provided evidence that the CSF 
Alzheimer profile characterized by decreased Aβ1–42 or an elevated tau/Aβ1–42 ratio clearly 
identifies subjects positive for Aβ plaque and tangle burden who are therefore at risk for 
progression to AD [16,17], and this finding is consistent with that reported in many other 
studies [34,38–42]. These CSF biomarker data support their use for the early detection of 
AD despite the fact that different analytical platforms were used and that the patient 
populations were heterogeneous, and they also provide support for the revised research 
diagnostic criteria for AD dementia [11], MCI due to AD [10,12], and the definition of 
preclinical stages of AD [13]. However, differences in the concentration values for the AD 
CSF biomarkers across numerous studies that used different analytical platforms (i.e., 
ELISA, Luminex-xMAP, and Mesoscale Discovery platforms) have been observed. 
Therefore, reduction and control of analytical variability across laboratories is an important 
goal in this field, and efforts to minimize the analytical variability are underway (reviewed in 
[20] and see later for a more detailed discussion). The observed low agreement between the 
different proposed imaging and CSF neurodegeneration biomarkers indicates that each of 
these technologies has a different sensitivity and specificity to detect the earliest preclinical 
changes or to differentiate AD-related pathology from other neurodegenerative diseases 
[46].
The main findings from studies of the ADNI cohort since its inception in 2004 were recently 
updated, well-summarized, and discussed for their considerable clinical implications by 
Weiner and collaborators [47].
4.2. The heterogeneous pathologic features of AD
The brains of patients who have late-onset AD verified by neuropathologic diagnosis at 
autopsy have widespread distribution of amyloid-β plaques and neurofibrillary tangles that 
are the pathologic hallmarks of this disease. In addition, a significant number of AD patients 
at autopsy have one of more concomitant pathologic findings (comorbidities) including LBs, 
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vascular disease, TDP-43, hippocampal sclerosis, and argyrophilic grain disease. In the 
review of the first series of 22 brain autopsy cases of ADNI subjects that included 20 
subjects with a clinical diagnosis of AD and 2 with MCI, all had evidence of plaque and 
tangle pathology. Importantly, only four had pure AD pathology with the remainder having 
coincident pathologic diagnoses of dementia with Lewy bodies (DLB), TDP-43 
proteinopathy, argyrophilic grain disease, and hippocampal sclerosis [46]. This series is 
small in number and the future reporting of the neuropathologic findings in ADNI patients 
will help to substantiate these findings and enable correlation studies with CSF biomarkers. 
In a study of the association of AD CSF biomarkers in patients with autopsy-confirmed 
coincident neuropathology that included 142 Penn Alzheimer’s Disease Core Center 
(ADCC) subjects with “pure” AD, and AD combined with frontotemporal lobar 
degeneration (FTLD) pathology, including tau (FTLD-Tau) and TDP-43 (FTLD-TDP) 
inclusions or LBs [48], it was shown that CSF Aβ1–42 and t-tau levels outperformed clinical 
diagnosis to predict the presence of AD neuropathology. Vascular pathology is also 
frequently observed in demented subjects with AD pathology, and studies using ADNI 
subjects [49] and non-ADNI subjects [50] showed that vascular pathology measured by 
magnetic resonance imaging (MRI) may be associated with regional neurodegeneration or 
with CSF AD profile.
4.2.1. Detection of LB pathology in AD patients—The heterogeneous 
neuropathologic features frequently observed in clinically diagnosed AD patients may be 
reflected by distinct changes in additional CSF biomarkers such as decreased α-syn levels 
that are characteristic of LB pathology. The combination of AD-associated biomarkers with 
other CSF protein signatures has the potential to improve the diagnostic or prognostic 
performance as compared with tau and Aβ alone based on a study in 389 ADNI and 102 
subjects of the Parkinson’s Progression Markers Initiative [51]. Wang and collaborators 
reported additional diagnostic utility for phosphorylated CSF α-syn levels [52]. A mismatch 
between CSF α-syn and p-tau181 (lower level of α-syn and higher p-tau181 level) was tested 
in ADNI subjects to account for expected lower α-syn due to PD pathology compared with 
an increase associated with AD pathology. The inclusion of this mismatch in AD classifiers 
may improve the clinical performance of these CSF biomarkers [51].
4.2.2. Variable rates of decline for CSF Aβ1–42 may reflect AD disease 
heterogeneity—In addition to neuropathologic heterogeneity, the observation of 
longitudinal changes in CSF biomarker levels in the ADNI cohort revealed that there are 
distinct populations of subjects with normal baseline CSF Aβ1–42 values: those who remain 
stable and others who show a decline during follow-up (Fig. 3A–C) [43,45,53]. In the ADNI 
add-on study of the longitudinal trajectories of CSF biomarkers in 141 subjects with three or 
more CSFs collected longitudinally between 2005 and 2014, there were 35 whose baseline 
Aβ1–42 concentration values were above the 192 pg/mL cut point. The finding that 15 of 
these subjects (seven cognitively normal, eight MCI), followed longitudinally for 3–4 years 
from baseline, with normal baseline CSF Aβ1–42 had values declining toward the abnormal 
range at a mean annual change of −9.2 pg/mL is consistent with the hypothesis that these are 
individuals who have AD-like neuropathologic changes taking place in their brains at the 
time of their baseline visit as compared with the 20 subjects whose normal baseline values 
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were stable at a mean annual change of −0.5 pg/mL [53]. Interestingly, the majority (all but 
two) of the stable and decliner subjects was APOE ε4 negative (see Fig. 3B) and these 
patient subgroups were not statistically different at BASELINE for mean cognitive and 
memory tests, had comparable hippocampal volume values, but their Aβ1–42 values differed, 
257 versus 211 pg/mL (P < .001) [45], respectively. These preliminary data support the 
continued need for longitudinal lumbar punctures and CSF analyses in ADNI subjects to 
generate more statistically robust numbers of subjects with prolonged longitudinal 
biomarker profiles. ADNI is well positioned to provide larger numbers of subjects whose 
biomarker levels will move from normal values to pathological values as described in these 
ADNI studies [43,45,53] (Fig. 3A–C). Future studies are needed to assess what biomarker, 
imaging, and/or genetic factors predict which MCI and cognitively normal subjects with 
above cut point values for CSF Aβ1–42 are at risk to decline to pathologic values and 
significant Aβ plaque burden and progression to AD.
4.3. Multimodal approach including CSF biomarkers
Disease progression and AD endophenotypes appear to be influenced by both genetic and 
environmental factors. Baseline and longitudinal data from ADNI were used to explore the 
association between biomarkers and clinical parameters at different stages of the disease. As 
suggested by Jack and colleagues [54] and tested by Caroli and Frisoni [55] and others 
[56,57], individual biomarkers vary in their rate of change across different stages of AD. 
Results from the ADNI cohort supported the model of temporal progression of biomarker 
abnormalities [54,58]: a reduction in CSF Aβ1–42 (or increased plaque burden measured by 
Aβ amyloid PET) in cognitively normal NC subjects occurs first, followed by t-tau 
elevation, hippocampal atrophy, and ultimately clinical deterioration.
Based on this model of the dynamics for AD biomarkers according to the disease stage of 
AD, Walhovd reported an optimum combination of imaging and CSF biomarkers to 
differentiate NC from AD subjects. They have found that imaging biomarkers, but not CSF 
biomarkers, were significantly associated with changes in cognitive scores in the MCI group 
[59]. In non-ADNI subjects with MCI and evidence of Aβ amyloid pathology, the 
abnormality in injury markers (high CSF t-tau and hippocampal atrophy) could help to 
identify those subjects with MCI due to AD who will more rapidly progress to dementia 
[60].
Genetic factors, such as the APOE ε4 allele, may influence this rate of change. In addition to 
the effect of genetic factors on neurodegeneration, several other factors (e.g., smoking, body 
mass index) may modulate the disease trajectory although these results have been the subject 
of contradictory reports [61,62]. Based on the small number of cases that came to autopsy in 
the ADNI study, we found that, even in a study that was focused on typical AD cases, most 
of the subjects had coincident or comorbid neurodegenerative disease pathologies such as 
LBs or TDP-43 inclusions that were not diagnosed before death (Fig. 3D) [46]. These 
findings underscore the complexity of different factors that can contribute to DAT. The 
existence of heterogeneous subgroups with different clinical characteristics might have 
different prognoses and would potentially need different treatment approaches. In summary, 
combined multimodal analyses including CSF biomarkers, genetic factors, and different 
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imaging biomarkers and blood-based biomarkers continue to be a long-term aim for 
achievement of more accurate discrimination of AD from other neurodegenerative diseases 
and more accurate prediction of time course of disease progression in the individual patient 
[46].
The Biomarker Core will further determine in ADNI 3 which additional biomarkers could 
add to the predictive performance of CSF Aβ1–42, t-tau, and p-tau181.
5. Candidate new biomarkers
5.1. β-site amyloid precursor protein-cleaving enzyme 1 and soluble amyloid precursor 
proteins
β-site amyloid precursor protein-cleaving enzyme 1 (BACE1, β-secretase) is a membranous 
enzyme responsible to the production of Aβ species from amyloid precursor protein (APP). 
A sensitive and specific activity assay for BACE1 was previously developed [63,64]. The 
assay detected BACE1 enzyme activity in extracts of human brain tissues and, unexpectedly, 
in human CSF [65]. The expression level and activity of BACE1 in CSF was tested in ante-
mortem CSF samples of NC, MCI, and AD patients. BACE1 levels and activity were 
significantly increased in CSF of the MCI group as compared with NC and AD subjects 
[66]. Addition of CSF BACE1 activity and concentrations of α- and β-cleaved soluble APP 
(sAPPα and sAPPβ, respectively) could not improve the separation of AD from NC as 
compared with the performance of the classical AD biomarkers (Aβ1–42 and tau) [67]. When 
AD patients were classified in terms of disease severity, only MCI showed higher BACE 1 
activity as compared with AD or NC [66]. A recent study in the ADNI cohort found no 
significant differences in CSF BACE1 activity and sAPPβ concentrations between NC and 
stable MCI, progressive MCI, or AD patients, and no correlation with CSF Aβ1–42 or with 
plasma Aβ1–42 and Aβ1–40, but found some correlation with CSF tau levels [68]. Another 
study in ADNI-1 cohort with a small number of subjects with 2 years follow-up replicated 
negative results for diagnostic performance. There was no effect of APOE ε4 positive 
genotype on BACE1 activity or sAPPβ concentration, but males showed higher sAPPβ 
concentration than females. The significant correlation of BACE1 activity and sAPPβ 
concentration with tau proteins, consistent with the previous study, suggested that their 
correlation may be linked with neuronal/synapse number in the brain [69]. Although these 
results do not support the diagnostic utility of BACE1 activity in CSF, the correlation of 
BACE1 activity with sAPPβ and axonal degeneration supports their role as biomarkers for 
pharmacodynamics monitoring of BACE1-targeted clinical trials. Confounding factors 
including demographics may influence the poor diagnostic utility of CSF BACE1 activity 
for AD. More studies related BACE1 activity or protein levels are required.
5.2. Novel biomarkers discovered by rules based medicine multiplex immunoassay
A RARC approved add-on study used a Luminex bead-based immunoassay technology 
developed by Rules Based Medicine (RBM, Austin, TX) to screen CSF and plasma samples 
obtained from the ADNI cohort. First, a pilot study was conducted with non-ADNI Penn 
CSF samples to interrogate levels of 151 analytes with the Human Discovery Multi-Analyte 
Profile™ (MAP) panel. The panel was enriched in cytokines, chemokines, and growth 
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factors, and AD biomarkers in non-ADNI Penn CSF samples. This revealed novel CSF 
biomarkers (i.e., complement 3, neuronal cell adhesion molecule, and platelet-derived 
growth factor) that appeared to improve the distinction between AD and non-AD cases 
(including cognitively normal subjects) compared with established AD biomarkers alone 
[70]. Another study using non-ADNI CSF samples and a slightly larger number of analytes 
(N = 190) in the Human Discovery MAP 1.0 panel supported the results of the prior study 
and found additional CSF biomarkers (i.e., cystatin C, vascular endothelial growth factor 
(VEGF), tumor necrosis factor-related apoptosis-inducing ligand receptor 3, plasminogen 
activator inhibitor-1, pancreatic polypeptide, N-terminal prohormone of brain natriuretic 
peptide, matrix metalloproteinase-10, macrophage migration inhibitory factor, growth 
related oncogene-alpha, fibrinogen, FAS, and eotaxin-3) to improve the diagnostic utility for 
AD [71]. In an RBM study using CSF samples from the ADNI cohort, several markers were 
associated with neurodegeneration in Aβ amyloid-positive subjects but not in Aβ amyloid-
negative subjects. Lower levels of trefoil factor 3, VEGF, and chromogranin A, and a higher 
level of cystatin C were significantly associated with increased rates of neurodegeneration, 
indicating that these candidate markers potentially provide prognostic information and 
insights into AD pathobiology [72]. In another analysis of the multiplex RBM study of 
ADNI 1 CSF samples, high CSF apolipoprotein ε (apoE) levels were shown to be associated 
with a slower cognitive decline and decreased brain atrophy [126].
The RBM studies using ADNI CSF samples have been reported or are ongoing. RBM 
studies of targeted multiplex analysis of plasma proteins in ADNI samples supported the 
potential utility of a plasma proteome signature as a screening tool [73,74]. Of note, changes 
in the level of some plasma proteins (e.g., pancreatic polypeptide) were consistent with the 
results observed in CSF samples, and with results found in studies of non-ADNI cohorts 
[74,75]. These results also have been linked to genome-wide association studies (GWAS) 
[76] and provided novel insights into pathways and proteins that are associated with AD 
onset and progression.
5.3. Biomarkers quantified by multiple reaction monitoring tandem mass spectrometry
5.3.1. Amyloid beta (Aβ1–42)—Current immunoassays for Aβ measurement in CSF have 
several limitations including widely differing concentrations across the immunoassay 
platforms, using aliquots from the same samples, matrix effects, and lack of a CSF-based 
standard reference material and methodology [77]. The ADNI Biomarker Core continues to 
focus on assessments of CSF assays and other methodological issues related to the chemical 
biomarker studies conducted in the ADNI Biomarker Core at Penn. For example, Korecka et 
al. [78] established a calibrator surrogate matrix for the quantification of Aβ1–42 in human 
CSF. The analytical methodology was based on a 2-dimensional ultraperformance liquid 
chromatography/tandem mass spectrometry (2D-UPLC/MS-MS) platform and validated 
quality control samples were prepared for the liquid chromatography tandem mass 
spectrometry (LC/MS-MS) methodology. The surrogate matrix was artificial CSF containing 
4 mg/mL of bovine serum albumin which provided linear and reproducible calibration 
comparable with human pooled CSF as calibration matrix. The appropriate cleaning of the 
trapping and analytical columns provided daily trouble-free runs. Analyses of non-ADNI 
CSF Aβ1–42 showed that UPLC/MS-MS distinguished neuropathologically diagnosed AD 
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subjects from healthy NCs. The concentration of Aβ1–42 measured by the 2D UPLC/MS-MS 
system was on average 4.5 times higher compared with the concentration determined by 
Luminex-AlzBio3 immunoassay, however, the clinical utility was comparable [78]. ROC 
curve and correlation analyses evaluated the diagnostic utility of this mass spectrometry 
method compared with the AlzBio3 immunoassay for the detection of the AD CSF 
biomarker Aβ1–42. Comparison of ROC curves for these two assays showed no statistically 
significant difference (P =.2229). Linear regression analysis of Aβ1–42 concentrations 
measured by this mass spectrometry-based method compared with the AlzBio3 
immunoassay showed significantly higher but highly correlated results. Thus, this newly 
established surrogate matrix for 2D-UPLC/MS-MS measurement of Aβ1–42 provides 
selective, reproducible, and accurate results. The documented analytical performance and 
diagnostic performance for AD patients versus NCs supports consideration of this approach 
as a candidate reference method. This technique has also been evaluated in Round Robin 
studies, and compared with another mass spectrometry-based candidate RMP for CSF 
Aβ1–42 [79] with excellent results. Indeed the formal paperwork documenting the full details 
of this method has been submitted to the Joint Committee for Traceability in Laboratory 
Medicine as a candidate reference method.
5.3.2. Targeted mass spectrometry proteomic study—As the third part (the RBM 
study was the first, the BACE activity study the second) of the multiphased effort of the 
Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to identify 
CSF-based biomarkers in AD and to qualify multiple peptides in CSF, a targeted mass 
spectrometry proteomic study was performed by a subgroup of the industry PPSB of ADNI 
in collaboration with the FNIH Biomarker Consortium. The targeted proteins and peptides 
were selected based on their relevance to AD and results from RBM studies. Using the final 
panel consisting of 567 peptides representing 221 proteins, 320 of 567 peptides were 
detectable in >10% of 306 ADNI CSF samples. Multiple approaches to statistical analyses 
assessed whether these analytes were associated with diagnosis (NC vs. MCI and AD) or 
with the progression of MCI patients to DAT. The results identified several potential 
diagnostic or predictive biomarkers. For instance, hemoglobin A, hemoglobin B, superoxide 
dismutase showed value for differentiating patients, and neuronal pentaxin-2, neurosecretory 
protein nerve growth factor (VGF), and secretogranin-2 predict the progression of MCI to 
AD. These data provide a novel tool to improve diagnostic accuracy, predict the disease 
progression, evaluate treatment efficacy, and early diagnosis of AD [80]. Further studies are 
warranted to confirm these initial studies using isotope labeled internal standards and 
validated quantitative multiple reaction monitoring liquid chromatography/tandem mass 
spectrometry (mrm LC/MS-MS) methodology and/or validated immunoassays.
5.4. Neurogranin
Synaptic pathology seems to occur early in AD [81,82] and is the best correlate to the 
cognitive dysfunction in AD patients. Neurogranin is a postsynaptic protein expressed in 
dendritic spines and is implicated in synaptic plasticity. In the post-mortem brain tissue from 
early onset and late-onset AD patients, a reduction of neurogranin levels was observed as 
compared with NC subjects [83]. A preliminary study measuring neurogranin in CSF by 
semiquantitative immunoblot analysis after enrichment showed a significant increase of 
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neurogranin in the AD group compared with the NC group [84]. Based on this finding, using 
a newly developed monoclonal antibody and ELISA method, Kvartsberg et al. [85] 
supported the prior findings in two pilot cohorts and one independent validation cohort. 
They observed a marked increase in CSF neurogranin level in AD and found that high level 
of neurogranin in MCI stage subjects predicted the progression to AD particularly in Aβ 
amyloid-positive MCI patients during the follow-up period. These results suggested that 
CSF neurogranin may be a useful biomarker in addition to the established CSF AD 
biomarkers and has potential as a prognostic biomarker. To confirm these results, a study to 
measure CSF neurogranin using electrochemiluminescence technology in ADNI-1 samples 
has been conducted and data were recently uploaded to the ADNI database (https://
ida.loni.usc.edu). The study demonstrated that CSF neurogranin levels in AD and 
progressive MCI patients, particularly in Aβ amyloidpositive patients, are higher than NC 
subjects, and that high baseline neurogranin levels in the MCI group predicted disease 
progression as reflected by cognitive decline, decrease of cortical glucose metabolism 
evaluated by FDG-PET, and hippocampal volume loss measured by MRI during follow-up 
period.
6. Progress in standardization of CSF AD biomarker measurements
A hallmark of ADNI is the longstanding commitment to the standardization of all 
methodologies used in this study. As discussed earlier there is a wide variance across centers 
using various immunoassays, especially for the measurement of Aβ1–42. An important 
ingredient of the process of standardization of these methods is collaboration with other 
organizations and laboratories to produce protocols that provide for this on a worldwide 
basis and with as much expertise as can be assembled. It is also worth noting that the 
Coalition Against Major Diseases has worked diligently to engage the discussion with the 
United States Food and Drug Administration (US FDA) regarding the qualification of MRI-
based hippocampal volume and CSF AD biomarkers for specified use in treatment trials. A 
formal letter of support was issued by the FDA on 2/26/2015 to CAMD “…to encourage the 
further study and use of CSF analytes Ab1-42, t-tau and phopsho-tau, as exploratory 
prognostic biomarkers for enrichment in trials for Alzheimer’s disease” (http://
www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM439713.pdf). A very 
important part of those formal discussions has been the foundational value of highly 
standardized preanalytical and analytical methodology [86]. A major commitment to 
improve on the standardization of CSFAD biomarker measurement, that the ADNI 
Biomarker Core participates in, is the joint effort involving AD biomarker researchers from 
academic, industrial, and governmental laboratories, under the auspices of the Alzheimer’s 
Association GBSC and the International Federation of Clinical Chemistry (IFCC) and the 
Institute for Reference Materials and measurements (IRMM) [19]. Among the projects that 
are well-underway in this program are the joint study and development of mass spectrometry 
accuracy-based measurement of Aβ1–42 in CSF. Four participating centers including 
colleagues from Waters, PPD, the University of Gothenburg, and Penn, all use a common 
direct sample preparation method and clean-up step but different calibrator matrices and 
batches of Aβ1–42 standard [78,79,87,88]; all use isotope-labeled Aβ1–42 as internal 
standard. A pilot interlaboratory study was conducted in which aliquots from 12 CSF pools 
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that covered a 4.5-fold range of Aβ1–42 concentration were analyzed for the documentation 
of interlaboratory variation: R2 = 0.98; average intralaboratory %CV of 4.7%; 
interlaboratory %CV of 12.2% that improved to 8.3% when adjusted using a common 
calibrator (Pannee J, et al., manuscript in review). This was a proof-of-principle study that 
showed very good concordance across the four laboratories and provided evidence that the 
use of a common calibrator could further improve interlaboratory agreement. That 
hypothesis was first tested in a two-center (UGot and Penn) study in which the participating 
laboratories used Aβ1–42 standard prepared by IRMM for calibrator preparation in each 
center, and the linear regression analyses of 10 CSF pools in this preliminary study (R2 = 
0.99; Y = 1.021X-11.8) support the hypothesis that use of a common calibrator standard can 
provide for near-equivalent results in two different laboratories using two different 
calibration matrices [78,88]. The development of a reference Aβ1–42 standard has been 
underway by the IRMM during the past year and should have final Aβ1–42 mass assignment 
in the near future, pending final amino acid analysis-based mass analyses. This reference 
preparation has been used for a follow-up five-center interlaboratory study all using this 
common standard for calibrator preparation, and results of this study are expected to be 
available later this year, and provide a further test for the impact of use of a common 
calibration standard on interlab-performance. In addition to this interlaboratory study, the 
IRMM has organized a commutability study in which seven different immunoassays are 
compared with each other and to reference LC/MS-MS using aliquots from 32 different CSF 
samples. The results of these studies will hopefully provide the first major step toward the 
goal of true harmonization and ultimately, achievement of a common cut point for Aβ1–42. 
The IRMM working in concert with the GBSC team and direction of the IFCC CSF 
biomarker working group, chaired by Kaj Blennow, is developing a CSF-based certified 
reference material (CRM), consisting of aliquots of a large (5L) volume CSF pools, will 
have Aβ1–42 values assigned measured using qualified mrm/LC/tandem mass spectrometry 
reference methods. The CRM will have three different levels (low, intermediate, and high) of 
Aβ1–42 to cover the measuring range. Once available, this standard reference material would 
serve as a common commutable reference point for manufacturers of immunoassays to 
calibrate their standards against. This step could go a long way toward the goal of greatly 
improved agreement across the various immunoassay platforms (see Table 2 for basic 
information on new automated immunoassays).
7. Update on the blood-based AD biomarker development project
7.1. Blood-based proteome biomarkers
Although imaging and CSF biomarkers are the most promising tools to detect early AD in 
the controlled settings of a clinical study and demonstrate how AD biomarkers relate to AD 
pathophysiology, these modalities have the disadvantage of cost and invasiveness. It has 
been widely recognized that there remains a very compelling need for less costly and less 
invasive, and more widely available blood-based biomarkers for AD. Considering the 
multistage diagnostic process that is common in medical practice, simple and cost-effective 
blood-based biomarkers can enhance the utility of CSF and imaging biomarkers. One of the 
earliest blood-based biomarker studies were conducted by Ray et al. [89]. They identified 18 
plasma proteins of 120 proteins using the predictive analysis of microarray that 
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discriminated AD from nondemented NC subjects with close to 90% accuracy and predicted 
the progression of MCI with overall 81% agreement. Although this work has not been 
replicated, numerous profiling approaches using proteomic technology including RBM 
Human Discovery MAP system and multiplex array ELISA were conducted within and 
outside ADNI and some promising candidates were detected (e.g., N-terminal prohormone 
of brain natriuretic peptide and pancreatic polypeptide) for early diagnosis and severity of 
AD [73–75,90–94]. A recent systematic review and replication study found that nine of the 
previous reported candidates were associated with AD-related phenotypes, and the 
association of pancreatic prohormone and insulin-like growth factor-binding protein 2 with 
AD was replicated [95]. A recent study of pairwise gene–protein relationship integrating 
multiplex-panel plasma proteomics and targeted genes from GWAS data in ADNI and non-
ADNI cohorts proposed the consideration of genetic variation when plasma protein levels 
are evaluated [96]. Therefore, combinations of these proteins appear to be promising 
directions to pursue for blood-based AD biomarkers, although validation studies should be 
conducted in large longitudinal population-based cohorts. Furthermore, these blood-based 
profiles of proteins will provide an insight for pathology and/or pathogenesis of AD [97]. 
However, the current blood-based proteomic or multiplex approaches as potential diagnostic 
and/or prognostic AD biomarkers are far from realistic clinical practice and validation 
studies are needed. Instead, these may play an increasing role in development of therapeutic 
targets or in monitoring response to therapy. Indeed, a recent study of subjects in the ADNI 
cohort using a multiplex immunoassay panel suggested that the incorporation of plasma 
biomarkers could yield high sensitivity and improved specificity, supporting their usefulness 
as a screening tool [73].
7.2. Plasma Aβ species
Like CSF, plasma Aβ species have been one of the first targets investigated, and are the most 
extensively studied peripheral marker for AD and still of substantial interest. However, the 
results of plasma level or ratio of Aβ species in sporadic AD, compared with NC, have been 
contradictory. Increased levels of Aβ1–42 in AD were reported [98], but another study 
reported the opposite [99,100]. In studies that classified subjects not only based on clinical 
diagnosis but also on AD-like CSF signature, that is, high t-tau and low Aβ1–42, the group of 
NC and MCI subjects with an AD-like CSF signature showed lower plasma Aβ1–42/Aβ1–40 
ratio when compared with subjects with a normal CSF signature [101] and this also is the 
case for studies of MCI and AD patients [102]. Taken together, studies to determine plasma 
Aβ levels have not been useful as a diagnostic tool. Instead of diagnosis, when cognitive 
measures were used as outcome, the association between plasma Aβ levels or ratios and rate 
of cognitive decline was not consistent [101,103–105]. A recent study in the ADNI cohort 
measuring plasma Aβ species with other imaging and CSF biomarkers revealed that plasma 
Aβ1–42 showed only mild correlation with other biomarkers of Aβ pathology (CSF for 
soluble Aβ and Pittsburgh compound B (PiB)/AV-45 PET for insoluble Aβ measurement) 
and infarctions (white matter hyperintensity revealed by MRI), and a number of health 
conditions were associated with altered concentrations of plasma Aβ [30,106]. Weak 
association of plasma Aβ levels with cognitive changes consistent with previous conflicting 
results may be influenced by variable health factors [107]. It is not clear whether the level of 
plasma Aβ1–42 or Aβ1–40 reflects Aβ production and/or clearance in the brain because Aβ 
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species in the blood are not all from the brain. Considering the production of Aβ1–42, β-
secretase is a rate-limiting enzyme in Aβ-APP processing. Perneczky et al. reported that 
CSF β-secretase activity was not correlated with CSF Aβ1–42, plasma Aβ1–42, and plasma 
Aβ1–40, but with t-tau and p-tau in CSF, indicating that CSF levels of Aβ1–42 most likely 
reflect its deposition by decreased clearance rather than increased production in sporadic AD 
[68]. These studies and a recent review underlined the need for a better understanding of the 
biology and dynamics of plasma Aβ particularly in sporadic AD and for longer-term studies 
to determine the clinical performance of plasma Aβ [108]. However, with the improvement 
of the assay conditions, standardization of preanalytical and analytical processes, and full 
consideration of confounding factors affecting plasma Aβ levels, it is possible that plasma 
Aβ levels may become useful as a biomarker of brain Aβ amyloidosis and 
pharmacodynamics of Aβ-targeted therapy in AD.
7.3. Genetic biomarkers
The high heritability of late-onset AD (~80% heritability from twin studies) [109,110] 
derived a number of genetic association studies, and APOE ε4 allele is the best established 
genetic risk factor for risk to develop AD. The role of the ε4 allele as a modulator of the 
relationship between plasma Aβ and Aβ pathology in the brain (Aβ amyloid PET) was 
assessed in ADNI subjects. In APOE ε4− but not ε4+ subjects, there was a positive 
correlation between plasma Aβ1–40/Aβ1–42 ratio and [11C]PiB uptake [111]. Another study 
demonstrated that the expression pattern of plasma proteins determined by multiplex RBM 
panel was associated with APOE allelic status [73]. These results suggest that APOE 
genotype is associated with a unique plasma protein profile irrespective of diagnosis, 
indicating the importance of APOE genotype on plasma biomarker profiles.
Recent GWAS and meta-analysis studies identified and confirmed additional genetic variants 
associated with AD including CLU, PICALM, CR1, MS4A4A, CD2AP, CD33, EPHA1, 
BIN1 and ABCA7 and APOE [112–116]. Some specific single nucleotide variants in novel 
genes detected by robust sequencing technology (e.g., next-generation sequencing) were 
significantly associated with the progression of hippocampal atrophy in MCI patients 
without APOE ε4 allele [117,118]. These genetic data may have predictive value when 
combined with imaging and/or fluid biomarkers, and provide novel candidate 
therapeutic.target
7.4. Novel neuron-specific blood exosome biomarkers
Recently, two articles in non-ADNI cohorts were published and reported on the clinical 
utility to discriminate MCI/AD from matched NC subjects or patients with frontotemporal 
degeneration (FTD) using neural-derived blood exosomal proteins [119,120]. Fiandaca et al. 
measured AD-related proteins (i.e., Aβ1–42 and tau proteins) in neural-derived exosomes 
separated from peripheral blood (plasma), and found 96.4% accuracy for AD and 87.5% for 
FTD from NC subjects. They suggested that levels of phosphorylated tau and Aβ1–42 in 
extracts of neural-derived plasma exosomes predict the development of AD up to 10 years 
before clinical onset. Kapogiannis et al. examined phosphorylated type 1 insulin receptor 
substrate (IRS-1) related to insulin signaling pathways in neural exosomes in blood, and 
showed a complete separation of AD from NC subjects with normal cognition and without 
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insulin resistance using an insulin resistance index (p-Ser 312-IRS-1/pan pY-IRS-1 ratio). 
This finding supported an observation of increased extent of IRS-1/-2 abnormalities in MCI 
and AD patients in a large number of autopsy-derived brain samples [121]. However, they 
showed a lack of any relationship of levels of the IRS-1 proteins to severity and stage of AD, 
and some overlap between AD and cognitively intact NC subjects with insulin resistance. 
These studies show promise to identify novel blood-based biomarkers specific to brain 
pathology that may give insights in the understanding of pathogenesis in preclinical stage of 
AD. However, further studies will be needed to validate these findings in independent 
clinical cohorts with larger numbers of subjects and with longitudinal clinical, CSF and 
imaging data including the ADNI cohort. Furthermore, the standardization of methodologies 
to extract neural-derived exosome and to measure exosomal proteins using ELISA will be 
required to confirm the validity of this approach.
7.5. Standardization of blood-based biomarker measurement
For the standardization of preanalytical variables for blood-based biomarker studies, the first 
set of guidelines was recently published by an international working group of the Standards 
for Alzheimer’s Research in Blood biomarkers (STAR-B) and Blood-Based Biomarker 
Interest Group (BBBIG) after initial overview regarding the status of the field [122,123]. 
The principle of the guidelines for preanalytical methods for blood-based AD biomarker by 
BBBIG/STAR-B working group are generally not specific but follow the regulatory good 
laboratory practice as defined by Clinical Laboratory Improvement Amendment in United 
States or international standards of Clinical Laboratory Standards Initiative. For blood-based 
biomarker studies in AD to progress, the adoption of guidelines to standardize preanalytical 
methods across cohorts and laboratories is required. Therefore, the BBBIG/STAR-B 
guidelines are a good starting point toward standardized methods that will be essential to 
move putative blood-based biomarkers forward in additional studies.
Changes in blood-based biochemical end points may not reflect pathology in the brain, 
compared with CSF signatures. Nevertheless, the recent literature suggests that several 
blood-based biomarkers or patterns will be useful to discriminate early AD and to predict 
the disease progression. However, the most important issues that remain are: adoption of 
standardized methodologies for sample collection and other preanalytical processes, method 
validation including establishing prospective quality control protocols and identification and 
control of matrix interferences consideration of how the diagnosis status is defined (e.g., 
pathology vs. clinical) and of comorbidities, confirmation of the results in independent 
studies, and independent assays [122]. In addition, blood-based biomarkers that can 
represent brain-specific pathology (e.g., neuron-specific exosome study) will warrant the 
clinical utility of blood-based biomarkers for the early detection of AD and prediction of the 
disease progression, and finally facilitate the clinical use of CSF and imaging biomarkers, 
the development of biomarkers closer to clinical routines and disease-modifying drug 
development. Regarding the role of the ADNI Biomarker Core in biomarker standardization, 
it should be noted that multiple collaborative efforts related to standardization consensus, 
discovery, or validation of novel blood-based biomarkers, collaborations with or support 
from international entities for blood-based biomarker development are emerging.
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RESEARCH IN CONTEXT
1. Systematic review: The authors described progress made by the ADNI 
Biomarker Core, on use and application of standardized methodology, 
based on reviews of the literature using traditional (eg, PubMed) 
sources and meeting abstracts on CSF and plasma biomarker data 
generated by the core. Selected non-ADNI studies were included to 
enable wider interpretation across different populations of AD and 
control subjects.
2. Interpretation: Plaque and tangle pathology are reliably detected in 
prodromal and preclinical stages of AD using CSFAβ1-42 and tau 
protein concentration measurements and cutpoints established in the 
ADNI study. The trajectories over time for these biomarkers 
characterize progression to the pathologic state and heterogeneity 
across each ADNI cohort.
3. Future directions: With an emphasis on the use of automated and 
highly standardized methods, and including new biomarker tests, the 
Penn ADNI Biomarker Core will continue studies of baseline and 
longitudinal samples to enhance the predictive performance of CSF and 
plasma biomarkers. Continued collaboration using multimodal 
approaches are planned.
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Fig. 1. 
This figure is a newly adapted schematic depicted in two previous Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) reviews [47,124] that updates the current understanding of 
the hypothetical time line for the onset and progression of Alzheimer’s disease (AD) 
neurodegeneration and cognitive impairments progressing from normal controls (NC) to 
mild cognitive impairment (MCI) and then to AD. Age is indicated at the bottom, whereas 
the green, blue, and red bars indicate the time at which preventive, disease-modifying, and 
symptomatic interventions, respectively, are likely to be most effective. Within the aqua bar 
are shown milestones in the pathobiology of AD that culminate in death and autopsy 
confirmation of AD. The proposed ADNI model of the temporal ordering of biomarkers of 
AD pathology relative to stages in the clinical onset and progression of AD is shown in the 
insert at the upper right based on Jack et al. [58], whereas the insert at the left illustrates the 
defining plaque and tangle pathologies of AD and common comorbid pathologies including 
Lewy body pathology (LBP), transactive response DNA binding protein 43 kDa (TDP-43), 
and hippocampal sclerosis. In the insert on the right, clinical disease is on the horizontal axis 
and it is divided into three stages; cognitively normal, MCI, and dementia. The vertical axis 
indicates the range from normal to abnormal for each of the biomarkers and for measures of 
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memory and functional impairments. The plot in the upper right of this figure is taken from 
reference #58 with permission.
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Fig. 2. 
Summary of (1) biofluid tracking: time from sample collection to freezing for Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) cerebrospinal fluid (CSF) and plasma samples and 
(2) ADNI GO/2 number of biofluids collected and number of aliquots in the Penn ADNI 
Biobank and the total of ADNI 1/2/GO biofluids collected and banked as of January 26, 
2015. This collection time data for each ADNI biofluid sample is tracked in the Penn ADNI 
Biofluid Biobank database.
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Fig. 3. 
(A) Plot of cerebrospinal fluid (CSF) amyloid beta (Aβ1–42) concentration (pg/mL) versus 
time (years) before florbetapir scan in the 27 normal, 17 mild cognitively impairment (MCI), 
and 16 Alzheimer’s disease (AD) subjects in the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) study. These are the subjects who participated in the ADNI longitudinal 
CSF biomarker study and who also had a florbetapir scan. Each colored line corresponds to 
an individual subject and each point on a line corresponds to a CSFAβ1–42 value from a 
single lumbar puncture (with permission from reference #43). The horizontal dotted line in 
each panel represents the CSFAβ1–42 cutoff value of 192 pg/mL. (B) Plot of the change 
(pg/mL/year) in CSFAβ1–42 concentration during 3–4 years follow-up time (Y axis) versus 
CSFAβ1–42 concentration at baseline in the 141 ADNI subjects who participated in the 
longitudinal CSF biomarker study (with permission from reference #53). The green circle 
includes the 20 study participants whose baseline Aβ1–42 value was normal (above 192 
pg/mL) and whose Aβ1–42 value remained stable at an average yearly rate of −0.5 pg/mL/
year for 3–4 years; the red circle includes the 15 participants whose baseline Aβ1–42 value 
was normal and whose Aβ1–42 value declined at an average yearly rate of −9.2 pg/mL/year 
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over 3–4 years. (C) Plot of CSFAβ1–42 concentration (pg/mL) versus time for the 35 
participants whose Aβ1–42 values were normal (above the 192 pg/mL cutoff) in the ADNI 
longitudinal study. The horizontal dashed line corresponds to the Aβ1–42 cutoff value (with 
permission from reference #45). (D) Heatmaps summarizing the semiquantitative 
neuropathological grading (from left to right: amyloid deposits, neurofibrillary tangles 
(NFT), Lewy bodies (LBs), and neuronal cytoplasmatic TDP-immunoreactive inclusions 
(NCI) for the different neuropathologic diagnostic groups (from top to bottom: AD, AD + 
medial temporal lobe (MTL) pathology, AD + dementia with Lewy bodies (DLB), AD + 
DLB + MTL pathology, and DLB + MTL pathology) (with permission from reference #46).
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